Enara Bio, a UK-based biotechnology company developing T-cell immunotherapies targeting novel "Dark Antigens" in solid tumours, has announced the appointment of Stacey Davis as both Chief Business Officer (CBO) and Chief Financial Officer (CFO).
The dual appointment marks a significant step for the Oxford biotech firm as it accelerates the development of its T-cell engager pipeline and prepares for its next phase of clinical and commercial growth.
In her combined role, Davis will oversee business development, corporate strategy, and financial operations. The company said her leadership will be central to advancing Enara's platform and securing strategic partnerships and funding.
Kevin Pojasek, Chief Executive Officer of Enara Bio commented “Stacey will play a crucial role in shaping our business development and capital strategy, strengthening our ability to forge strategic partnerships and secure the funds needed to accelerate our promising pipeline."
Her appointment comes as Enara strengthens its executive team and board amid increasing investor and industry interest in targeting cancer-associated antigens that are not typically visible to the immune system.
Davis brings more than 25 years of experience in life sciences, spanning senior roles across business development, strategy, and commercial operations. She most recently served as Chief Business Officer at Xilio Therapeutics, where she played a key role in advancing strategic partnerships and leading investor engagement. Prior to that, she held leadership positions at Novartis Oncology, Johnson & Johnson, and several early-stage biotech companies in the US and Europe.
She holds a Bachelor of Science in Biomedical Engineering from Duke University.
Enara Bio is part of Oxford’s growing life sciences cluster and is backed by investors including RA Capital Management, Pfizer Ventures, and M Ventures. The company is developing a proprietary pipeline of T-cell engagers that target previously unaddressable tumour antigens through its EDAPT® platform.
The addition of Davis is expected to strengthen the company’s commercial focus as it positions itself for further partnerships and funding rounds ahead of clinical entry.
Founded in 2016, Enara Bio is developing next-generation T-cell therapies aimed at unlocking a new class of cancer targets known as Dark Antigens. These antigens are derived from normally hidden parts of the genome and are believed to play a role in tumour evolution and immune evasion.
